Melanie Salek

Melanie Salek

Auto-generated profile, based on publicly available information

Melanie Salek

Department of Dermatology, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2026 in Nature Communications
Verified
Journal Article
Open access
MDMartin Direder
Martin Direder
MWMatthias Wielscher
Matthias Wielscher
MSMelanie Salek
Melanie Salek
MLMaria Laggner
Maria Laggner
DCDragan Copic
Dragan Copic
BMBernhard Moser
Bernhard Moser
The human thymus plays a key role in the development of the adaptive immune system. Its development and pathologic aberrations with missing involution occupy the scientific world for years. Here, we present a comprehensive single-cell RNA sequencing (scRNA-seq) analysis of 453,727 cells across 53 datasets derived from healthy prenatal, pediatric, and adult thymic tissues, as well as six pathological conditions, including thymic hyperplasia and thymic epithelial tumors (types A, AB, B, C, and micronodular thymoma). We created a high-resolution cellular atlas revealing disease-specific cellular populations and transcriptional programs, particularly within fibroblast subsets and thymic epithelial cells. Comparative analysis uncovers distinct intercellular communication patterns and identifies transcriptional alterations associated with thymic pathology. Integration with published bulk RNA-seq datasets supports the robustness and translational relevance of our findings. This study provides a foundational resource for understanding the cellular and molecular landscape of thymic development and disease, offering avenues for diagnostic and therapeutic innovations.

28 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DHDalia Hamid
Dalia Hamid
LALisa Auer
Lisa Auer
SMStefan Mohr
Stefan Mohr
SGSylwia Gazda-Miarecka
Sylwia Gazda-Miarecka
MSMelanie Salek
Melanie Salek
GBGianluca Bello
Gianluca Bello
APOSEC TM , a complex mixture of secreted proteins, lipids, and extracellular vesicles from stressed peripheral blood monocytes, is currently in clinical trials for the treatment of chronic, poorly healing wounds. When applied to open wounds, 1 mL reconstituted APOSEC TM lyophilisate is syringe-mixed with 3 g sterile hydrogel prior to administration. This study investigates the pharmaceutical performance of this novel administration system. A gel formulation (APOgel) was developed for terminal sterilisation in pre-filled syringes with post-sterilisation viscosity (∼325-350□Pa*s at 1□s -1 ) comparable to a commercial benchmark gel. Syringe mixing of APOgel with a liquid APOSEC TM surrogate (3:1) reduced viscosity by ∼67% but was highly reproducible across different operators (CV < 6%). Administration of three sequential dose units of the mixture from the syringe revealed an ∼20% higher content of active ingredients in the first and final dispensed compared to the middle unit, indicating non-uniform mixing in the closed syringe system. In vitro release studies over 72□h showed a 32% and 48% higher release of a small molecule marker and total proteins from the sterile APOgel compared to the benchmark gel as well as more pronounced gel swelling. However, efficacy studies in a murine wound healing model showed no significant difference between APOgel and the benchmark. These findings indicate that terminal sterilisation of gels for topical applications may provide benefits for more rapid release of active agents but syringe mixing of gels and a liquid requires optimisation to ensure uniform drug distribution. Highlights: An autoclavable hydrogel for APOSEC TM delivery was developed A novel syringe-mixing system for combining a gel with a liquid with subsequent dispensing of different volume units showed non-homogenous active ingredient distribution Final optimised APOSEC TM -APOgel formulation maintains functional wound-healing efficacy

6 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
DHDalia Hamid
Dalia Hamid
LALisa Auer
Lisa Auer
SMStefan Mohr
Stefan Mohr
SGSylwia Gazda-Miarecka
Sylwia Gazda-Miarecka
MSMelanie Salek
Melanie Salek
GBGianluca Bello
Gianluca Bello
APOSECTM, a complex mixture of secreted proteins, lipids, and extracellular vesicles from stressed peripheral blood monocytes, is currently in clinical trials for the treatment of chronic, poorly healing wounds. When applied to open wounds, 1 mL reconstituted APOSECTM lyophilisate is syringe-mixed with 3 g sterile hydrogel prior to administration. This study investigates the pharmaceutical performance of this novel administration system. A gel formulation (APOgel) was developed for terminal sterilisation in pre-filled syringes with post-sterilisation viscosity (~325-350 Pa*s at 1 s-1) comparable to a commercial benchmark gel. Syringe mixing of APOgel with a liquid APOSECTM surrogate (3:1) reduced viscosity by ~67% but was highly reproducible across different operators (CV < 6%). Administration of three sequential dose units of the mixture from the syringe revealed an ~20% higher content of active ingredients in the first and final dispensed compared to the middle unit, indicating non-uniform mixing in the closed syringe system. In vitro release studies over 72 h showed a 32% and 48% higher release of a small molecule marker and total proteins from the sterile APOgel compared to the benchmark gel as well as more pronounced gel swelling. However, efficacy studies in a murine wound healing model showed no significant difference between APOgel and the benchmark. These findings indicate that terminal sterilisation of gels for topical applications may provide benefits for more rapid release of active agents but syringe mixing of gels and a liquid requires optimisation to ensure uniform drug distribution.

3 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
HKHannes Kühtreiber
Hannes Kühtreiber
DBDaniel Bormann
Daniel Bormann
MSMelanie Salek
Melanie Salek
THThomas Haider
Thomas Haider
CMCaterina Selina Mildner
Caterina Selina Mildner
Michael MildnerMichael Mildner
Michael Mildner
Burn injuries often lead to severe complications, including acute respiratory distress syndrome (ARDS), driven in part by systemic inflammation and glycocalyx disruption. In this study, we analyzed the sera of 28 patients after burn trauma and utilized transcriptomic analyses to decipher the impact of burn injury on glycocalyx derangement. We observed significant upregulation of immune cell-derived degrading enzymes, particularly matrix metalloproteinase-8 (MMP8), which correlated with increased immune cell infiltration and glycocalyx derangement. Serum analysis of burn patients revealed significantly elevated levels of shed glycocalyx components and MMP8, both correlating with the presence of inhalation injury. Consequently, treatment of human in vitro lung tissue models with MMP8 induced significant glycocalyx shedding in both, the endothelium and epithelium. Together our data suggest MMP8 as a contributor of glycocalyx disruption and lung injury post-burn.

30 April 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DHDalia Hamid
Dalia Hamid
LALisa Auer
Lisa Auer
SMStefan Mohr
Stefan Mohr
SGSylwia Gazda-Miarecka
Sylwia Gazda-Miarecka
MSMelanie Salek
Melanie Salek
GBGianluca Bello
Gianluca Bello